The Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Consensus Conference on Clinical Research (ECCC) was held in Incheon, South Korea, Nov 2–3, 2023. The aims were to develop consensus statements for future trials in endometrial cancer to achieve harmonisation on design elements, select important questions, and identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and finalisation of 18 statements within four topic groups, addressing adjuvant treatment in high-risk disease; treatment for metastatic and recurrent disease; trial designs for rare endometrial cancer subgroups and special circumstances; and specific methodology and adaptation for trials in low-resource settings. In addition, eight areas of unmet need were identified. This was the first GCIG Consensus Conference to include patient advocates and an expert on inclusion, diversity, equity, and access to take part in all aspects of the process and output. Four early-career investigators were also selected for participation, ensuring that they represented different GCIG member groups and regions. Unanimous consensus was obtained for 16 of the 18 statements, with 97% concordance for the remaining two. Using the described methodology from previous Ovarian Cancer Consensus Conferences, this conference did not require even one minority statement. The high acceptance rate following active involvement in the preparation, discussion, and refinement of the statements by all representatives confirmed the consensus progress within a global academic setting, and the expectation that the ECCC will lead to greater harmonisation, actualisation, inclusion, and resolution of unmet needs in clinical research for individuals living with and beyond endometrial cancer worldwide.

中文翻译：

---

子宫内膜癌的临床研究：妇科癌症 InterGroup 的共识建议


妇科癌症组间 （GCIG） 子宫内膜癌临床研究共识会议 （ECCC） 于 2023 年 11 月 2 日至 3 日在韩国仁川举行。目的是为子宫内膜癌的未来试验制定共识声明，以实现设计要素的协调、选择重要问题并确定未满足的需求。所有 33 个 GCIG 成员组都参与了四个主题组中 18 项声明的制定、完善和定稿，涉及高危疾病的辅助治疗;转移性和复发性疾病的治疗;罕见子宫内膜癌亚组和特殊情况的试验设计;以及资源匮乏环境中试验的具体方法和调整。此外，还确定了 8 个未满足需求的领域。这是第一次 GCIG 共识会议，包括患者倡导者和包容性、多样性、公平性和可及性方面的专家，以参与流程和产出的各个方面。还选择了四名早期职业研究人员参与，确保他们代表不同的 GCIG 成员群体和地区。18 项声明中的 16 项获得一致共识，其余两项获得 97% 的一致性。使用以前卵巢癌共识会议中描述的方法，本次会议甚至不需要一个少数派声明。所有代表积极参与声明的准备、讨论和完善后的高接受率证实了全球学术环境中的共识进展，以及 ECCC 将导致更大的协调、实现、包容和解决临床研究中未满足的需求全球子宫内膜癌患者和子宫内膜癌之外的个体。